Answers:
A. Erythrokeratolysis hiemalis e Incorrect. This autosomal dominant condition is characterized by episodic/seasonal circinate, erythematous plaques with scaling, and centrifugal peeling. It predominantly involves palms and soles and may extend up the extremities. It rarely involves the trunk and face. Blisters occasionally occur in the center of new plaques. 1 B. Erythrasma e Incorrect. Erythrasma is caused by Corynebacterium minutissimum overgrowth in the stratum corneum. Well-defined scaly plaques involve intertriginous sites of the trunk and toes. Coral red fluorescence on Wood's lamp examination is classic and was negative in this patient's case.
C. Tinea corporis and cruris e Incorrect. Tinea corporis and cruris are dermatophyte infections of the trunk, extremities, and groin, respectively. Classic lesions have advancing, scaly border and central clearing. Hyphae are seen on histopathology and potassium hydroxide preparation (KOH prep).
D. EKV e Correct. EKV, an autosomal dominant disorder, presents with transient erythematous patches and stable hyperkeratosis. Individual erythematous lesions persist for minutes to hours, although they may last for days. Simultaneously or over time hyperkeratosis evolves. Sharply demarcated, yellow-brown to pink-brown plaques with figurate borders progressively develop on the limbs, buttocks, and trunk in nearly symmetrical distribution. Histopathology shows orthokeratosis, basket-weave hyperkeratosis, moderate-to-severe acanthosis with prominent granular layer, papillomatosis, and dilated elongated capillaries with minimal perivascular inflammation in the papillary dermis. 2 E. PSEK e Incorrect. PSEK begins during infancy or early childhood with fixed, sharply demarcated polycyclic hyperkeratotic plaques on erythematous base with fine scale or a rough, verrucous surface. They are symmetrically distributed on extremities, buttocks, face, and occasionally the trunk. Transient erythema and relative sparing of the face differentiate EKV from PSEK. A. GJB3 and GJB4 e Correct. EKV is a disorder of cornification associated with noninflammatory erythema caused by dominant mutations in the connexin genes GJB3 and GJB4 clustered on human chromosome 1p35.1.
2 Connexins are transmembrane proteins that form intercellular channels. Mutations result in altered activity of gap junctions and cause impaired epidermal differentiation. Commercial genetic testing is available to identify missense mutations in the coding sequence of the GJB3 and GJB4 genes. Further information can be found at https://www.genedx.com/test-catalog/ disorders/erythrokeratodermia-variabilis-ekv.
B. SPINK5 e Incorrect. SPINK5 is a serine protease inhibitor kazal type 5 gene that is expressed in the lamellar granules of epithelium; its mutation results in increased proteolytic activity in the stratum corneum. SPINK5 mutation causes Netherton syndrome, an autosomal recessive disorder that may include clinical features of ichthyosis linearis circumflexa. 3 C. KRT14 e Incorrect. KRT14 plays a role in regulating apoptosis during morphogenesis of cutaneous appendages; its mutation results in susceptibility of keratinocytes to tumor necrosis factor aeinduced apoptosis. KRT14 mutation causes dermatopathia pigmentosa reticularis, an autosomal dominant disorder. A. Topical pimecrolimus e Incorrect. Topical pimecrolimus has shown no benefit in the treatment of EKV but can be used to treat ichthyosis linearis circumflexa. 3 
B.
Oral retinoid e Correct. Treatment of EKV is symptomatic and depends on the severity and extent of hyperkeratosis. Topical management with keratolytic agents such as lactic acid, urea, a hydroxy acids and tretinoin might be sufficient for mild disease. Systemic retinoids such as acitretin and isotretinoin are the treatment of choice for extensive EKV. C. Narrow-band ultraviolet B therapy e Incorrect. Narrow-band ultraviolet B therapy has shown no benefit in the treatment of EKV but can be used to treat ichthyosis linearis circumflexa. E. Ketoconazole cream e Incorrect. Ketoconazole cream has shown no benefit in the treatment of EKV but can be used to treat cutaneous dermatophyte infections.
Abbreviations used:
EKV: erythrokeratodermia variabilis PSEK: progressive symmetric erythrokeratoderma
